CEBPZ and acute myeloid leukemia: The rationale to use dasatinib against CBF-AML grounded on the frequently high KIT receptor tyrosine kinase expression and/or presence of KIT mutations in CBF-AML, as well as dasatinib efficacy against both wild-type and mutant KIT (Paschka et al., 2018).